In vitro and in vivo antifungal activities of TAK-456, a novel oral triazole with a broad antifungal spectrum

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 5, 2002, Pages 1388-1393

  Tsuchimori, Noboru ^a   Hayashi, Ryogo ^a   Kitamoto, Naomi ^a   Asai, Kentaro ^a   Kitazaki, Tomoyuki ^a   Iizawa, Yuji ^a   Itoh, Katsumi ^a   Okonogi, Kenji ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 1 METHYL 3 (1H 1,2,4 TRIAZOL 1 YL)PROPYL] 3 [4 (1H TETRAZOL 1 YL)PHENYL] 2 IMIDAZOLIDINONE; AMPHOTERICIN B; FLUCONAZOLE; ITRACONAZOLE; STEROL; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VORICONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CANDIDA ALBICANS; CANDIDIASIS; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOSIS; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; STEROL SYNTHESIS; SURVIVAL RATE;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CANDIDA ALBICANS; CANDIDIASIS; CRYPTOCOCCUS NEOFORMANS; FEMALE; FUNGI; IMIDAZOLES; MICE; MICROBIAL SENSITIVITY TESTS; TETRAZOLES;

EID: 0036237750     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.5.1388-1393.2002     Document Type: Article

References (30)

1. Antifungal resistance trend towards the year 2000. Implications for therapy and new approaches
2. Current and future antifungal therapy: New targets for antifungal agents
3. Formation of azole-resistant Candida albicans by mutation of sterol 14α-demethylase P-450
4. The mode of antifungal action of tolnaftate
5. Trends in anti-fungal use and epidemiology of nosocomial yeast infections in a university hospital
6. Aspergillosis
7. Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1
8. Human mycoses: Drugs and targets for emerging pathogens
9. Antifungal agents: Chemoytherapeutic targets and immunologic strategies
10. New antifungal agents
11. Effects of cyclodextrin on the pharmacology of antifungal oral azoles
12. Optically active antifungal azoles. XI. An alternative synthetic route for 1-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1, 2,4-triazol-1-yl)propyl]-3-[4-(1 H-1-tetrazolyl)phenyl]-2-imidazolidinone (TAK-456) and its analog
13. Invasive aspergillosis in patients with AIDS
14. Comparative pharmacokinetics of SCE-2787 and related antibiotics in experimental animals
15. Optically active antifungal azoles. X. Synthesis and antifungal activity of N-[4-(azolyl)phenyl]- and N-[4-(azolylmethyl)phenyl]-N′-[(1R,2R)-2-(2, 4-difluoro-phenyl)-2-hydroxy-1-methyl-3-(1H-1,2, 4-triazol-1-yl)propyl]azolones
16. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998
17. Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period
18. Susceptibilities of Norwegian Candida albicans strains to fluconazole: Emergence of resistance
19. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters
20. Fungal infections in the immunocompromised host
21. Fluconazole and other azoles: Translation of in vitro activity to in vivo and clinical efficacy
22. Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice
23. Recent advances in the epidemiology, prevention and treatment of invasive fungal infections in neutropenic patients
24. Increased mRNA levels of ERG16, CDR, and MDRI correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus
25. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients
26. Infections due to resistant Candida species in patients with cancer who are receiving chemotherapy
27. Statistical moments in pharmacokinetics